Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Emanuela Alessandra Castelli"'
Autor:
Elena Omati, Emanuela Oggionni, Renata Nozza, Mary Cabiddu, Fausto Petrelli, Cinzia Scolari, Emanuela Alessandra Castelli, Gianluca Perego
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(4)
Olaparib is a first-in-class PARP inhibitor that has demonstrated efficacy as maintenance therapy in patients with ovarian cancer. It has been approved as a capsule formulation and after the publication of data from SOLO2 study became available also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f40d828457a3b93c1265001001bdff
https://pubmed.ncbi.nlm.nih.gov/32041467
https://pubmed.ncbi.nlm.nih.gov/32041467
Autor:
Sandro Barni, Jens C. Hahne, Fausto Petrelli, Margherita Ratti, Michele Ghidini, Gianluca Tomasello, Rodolfo Passalacqua, Emanuela Alessandra Castelli, Laura Toppo
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
The association of folinate salts with 5-fluorouracil (5-FU) represents a gold standard in the treatment of many cancers. In several clinical trials, the simultaneous administration of calcium–folinic acid (Ca-FA) and the prolonged infusion of 5-FU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69787dd444cf96aaa73634a7780c0f97
https://doi.org/10.1177/1758835919853954
https://doi.org/10.1177/1758835919853954